NasdaqGM - Nasdaq Real Time Price USD
Silence Therapeutics plc (SLN)
4.7950
-0.3450
(-6.71%)
As of 2:45:06 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -0.31 | -0.3 | -1.16 | -1.06 |
| Low Estimate | -0.46 | -0.43 | -1.93 | -1.61 |
| High Estimate | -0.09 | -0.09 | -0.38 | -0.49 |
| Year Ago EPS | -0.43 | -0.73 | -0.99 | -1.16 |
Revenue Estimate
| Currency in GBP | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 7 | 7 |
| Avg. Estimate | 2.32M | 2.32M | 17.69M | 16.9M |
| Low Estimate | 101.51k | 96.25k | 412.06k | 395.52k |
| High Estimate | 4.51M | 4.51M | 49.23M | 35.9M |
| Year Ago Sales | 598k | 1.14M | 34.27M | 17.69M |
| Sales Growth (year/est) | 288.16% | 103.10% | -48.37% | -4.50% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.11 | -0.13 | -0.25 | -0.41 |
| EPS Actual | -0.43 | -0.73 | -- | -0.6 |
| Difference | -0.31 | -0.6 | -- | -0.19 |
| Surprise % | -273.58% | -477.55% | -- | -44.58% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.31 | -0.3 | -1.16 | -1.06 |
| 7 Days Ago | -0.43 | -0.44 | -1.05 | -1.15 |
| 30 Days Ago | -0.32 | -0.34 | -1.06 | -1.36 |
| 60 Days Ago | -0.32 | -0.34 | -1.06 | -1.36 |
| 90 Days Ago | -0.2 | -0.2 | -0.49 | -0.69 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | 1 | 1 | -- | 1 |
| Down Last 30 Days | 1 | 1 | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| SLN | 28.29% | 58.82% | -16.97% | 8.79% |
| S&P 500 | 13.32% | 2.61% | 7.73% | 13.77% |
Upgrades & Downgrades
| Maintains | Goldman Sachs: Sell to Sell | 5/9/2025 |
| Maintains | Morgan Stanley: Overweight to Overweight | 5/9/2025 |
| Maintains | Chardan Capital: Buy to Buy | 5/9/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/7/2025 |
| Maintains | Morgan Stanley: Overweight to Overweight | 3/5/2025 |
| Maintains | BMO Capital: Outperform to Outperform | 3/4/2025 |
Related Tickers
EWTX Edgewise Therapeutics, Inc.
14.34
-3.56%
MIRM Mirum Pharmaceuticals, Inc.
44.22
-2.47%
SLNO Soleno Therapeutics, Inc.
73.23
-2.43%
AURA Aura Biosciences, Inc.
6.02
+1.52%
DYN Dyne Therapeutics, Inc.
11.68
-5.35%
CNTA Centessa Pharmaceuticals plc
12.93
-2.04%
PEPG PepGen Inc.
1.4600
-7.59%
LXEO Lexeo Therapeutics, Inc.
3.1149
-11.76%
KPRX Kiora Pharmaceuticals, Inc.
3.1100
-1.58%
KYTX Kyverna Therapeutics, Inc.
2.2200
-7.17%